Antivirals against HIV-1

Clinics in Laboratory Medicine

Volumn 22, Issue 3, 2002, Pages 741-757

  Frank, Ian ^a  

^a Infectious Diseases Division   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OUTPATIENT; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS PATHOGENESIS;

ANTIVIRAL AGENTS; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL; VIRAL LOAD;

EID: 0036716873     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-2712(02)00016-1     Document Type: Review

References (49)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Population biology of HIV-1 infection: Viral and CD4+ T cell demographics and dynamics in lymphatic tissue
3. Quantitative image analysis of HIV-1 infection in lymphoid tissue
4. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
5. Viral dynamics in human immunodeficiency virus type 1 infection
6. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
7. Predominance of distinct viral genotypes in brain and lymph node compartments in HIV-1-infected individuals
8. Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood
9. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: Evidence for viral compartmentalization and selection during sexual transmission
10. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase
11. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
12. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
13. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
14. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
15. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
16. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
17. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
18. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
19. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
20. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315
21. Changes in thymic function with age and during the treatment of HIV infection
22. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection
23. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
24. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
25. Factors influencing survival in HIV infected patients treated with HAART
26. Viral drug resistance, adherence and pharmacokinetic indices in HIV-1 infected patients on successful and failing protease inhibitor based HAART
27. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
28. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
29. Frequency of lipodystrophy and factors associated with glucose/lipid abnormalities in a cohort of 650 patients treated by protease inhibitors
30. Lipodystrophy, glucose and lipid metabolism dysfunctions
31. Cardio- and cerebrovascular outcomes with changing process of anti-HIV therapy in 36,766 US verterns
32. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)
33. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection
34. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
35. HIV drug resistance profiles and clinical and virologic outcomes among HIV-infected subjects with stable detectable plasma viral loads <1,000 copies/mL for at least 12 months
36. The presence of nucleoside analogue mutations (NAMs) is highly correlated with reduced susceptibility to all NRTIs
37. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
38. Coexistence and coevolution of viral populations with distinct genotypes in patients failing treatment with protease inhibitors
39. Reduced susceptibility to NRTI is associated with NNRTI hypersensitivity to virus from HIV+ infected patients
40. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
41. Persistence of transmitted drug resistance among subjects with primary HIV infection not receiving antiretroviral therapy
42. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial
43. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter
44. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
45. Progression of HIV-1 infected drug-naive patients starting potent antiretroviral therapy: Multicohort analysis of 12,040 patients
46. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
47. Phenotypic resistance testing significantly improves response to therapy: A randomized trial (VIRA3001)
48. Incidence and nature of phenotype-genotype discordance: Maximizing the utility of resistance testing